Stocks Health care ROIV
NASDAQ · Health careRoivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd. brought in $7.5M of revenue over the twelve months to June 30, 2026, down 67.6% from a year earlier. It posted a net loss of $266.3M. In fiscal 2025 capital spending exceeded operating cash flow by $758.6M. At June 30, 2026 it held $1.2B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Roivant Sciences Ltd.
- Net worth
- Roivant Sciences Ltd. has a market value (market cap) of $25.8B at the latest share price, and shareholders' equity of $4.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $8.3M (-71.6% year on year), with a net loss of $299.8M. Over the 12 months to June 30, 2026: revenue $7.5M, net loss $266.3M.
- Cash flow
- In fiscal 2025 operations used $750.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Roivant Sciences Ltd.'s next report is expected around October 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Roivant Sciences Ltd. does
Roivant Sciences Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ROIV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $8.3M | -$299.8M | -$0.54 | -$758.6M |
| 2024 | $29.1M | -$172M | -$0.24 | -$844.1M |
| 2023 | $32.7M | $4.3B | $5.23 | -$766.7M |
| 2023 | $31.5M | -$1B | -$1.42 | -$856.1M |
| 2022 | $55.3M | -$845.3M | -$1.26 | -$695.2M |
| 2022 | $23.8M | -$809.2M | -$1.28 | -$557.9M |
Full financial statements: income, balance sheet and cash flow
Where ROIV ranks in Health care
Latest SEC filings
What Roivant Sciences Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Activist stake changed SCHEDULE 13D/A
- September 18, 2026
- September 8, 2026
- August 28, 2026Other event 8-K
- August 27, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 34% to $1.4M versus the same quarter last year; diluted EPS -$0.26 versus -$0.33.
- August 6, 2026
- July 29, 2026
- July 29, 2026Additional proxy material DEFA14A
Insider trades
What the people running Roivant Sciences Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $59.8M worth of shares in the last 90 days and bought none on the open market. 39% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Epperly Melissa B,Director | Exercised options | 17,750 | $79.2K |
| October 1, 2026 | Epperly Melissa B,Director | Soldpre-planned (10b5-1) | 16,850 | $607.9K |
| October 1, 2026 | Epperly Melissa B,Director | Soldpre-planned (10b5-1) | 900 | $32.9K |
| September 30, 2026 | Torti FrankPresident and Vant Chair | Shares withheld for tax | 40,309 | $1.5M |
| September 30, 2026 | Gline MatthewCEO, Director | Shares withheld for tax | 76,171 | $2.8M |
| September 30, 2026 | Venker EricPresident & Immunovant CEO | Exercised options | 200,000 | $770K |
| September 30, 2026 | Venker EricPresident & Immunovant CEO | Soldpre-planned (10b5-1) | 200,000 | $7.3M |
| September 30, 2026 | Sukhatme MayukhPresident & CIO, Director | Shares withheld for tax | 46,879 | $1.7M |
Who owns ROIV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Roivant Sciences Ltd.13D, may seek influence | 55.9% | December 12, 2025 |
| Fmr LLC13G, passive with 1 related filers | 10.3% | March 6, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 136,371,061 shares in total, about $4.88B at the last price.
| Holder | Shares |
|---|---|
| Ramaswamy Vivek10% owner | 33,653,755 |
| Gold Daniel AllenDirector | 22,654,98113,689,166 held indirectly |
| Sukhatme MayukhPresident & CIO, Director | 18,583,860 |
| Gline MatthewCEO, Director | 16,583,774 |
| Manchester Keith SDirector | 15,442,62313,689,166 held indirectly |
| QVT Financial LPDirector by Deputization | 13,689,16613,689,166 held indirectly |
| Torti FrankPresident and Vant Chair | 13,495,893 |
| Venker EricPresident & Immunovant CEO | 1,599,154 |
| Pulik RichardCFO | 269,681 |
| Oren IlanDirector | 123,680 |
Questions about ROIV
What does Roivant Sciences Ltd. do?
Roivant Sciences Ltd. is a company in the Health care sector, listed on NASDAQ as ROIV. Its shares trade on NASDAQ under the ticker ROIV.
What is Roivant Sciences Ltd.'s net worth?
Roivant Sciences Ltd. has a market value (market cap) of $25.8B at the latest share price, and shareholders' equity of $4.2B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Roivant Sciences Ltd. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $266.3M on revenue of $7.5M.
How much revenue does Roivant Sciences Ltd. make?
Over the twelve months to June 30, 2026 Roivant Sciences Ltd. reported revenue of $7.5M. That is 67.6% less than a year earlier.
When did Roivant Sciences Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from October 5, 2026.
When is Roivant Sciences Ltd.'s next earnings report?
Roivant Sciences Ltd.'s next report is expected around October 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ROIV with
Follow ROIV
Get an email when Roivant Sciences Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ROIV: get an email when it filesWhere the numbers come from
Financial figures are the values Roivant Sciences Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.